CA2804626C - Method for using expression of glutathione s-transferase mu 2 (gstm2) to determine prognosis of prostate cancer - Google Patents

Method for using expression of glutathione s-transferase mu 2 (gstm2) to determine prognosis of prostate cancer Download PDF

Info

Publication number
CA2804626C
CA2804626C CA2804626A CA2804626A CA2804626C CA 2804626 C CA2804626 C CA 2804626C CA 2804626 A CA2804626 A CA 2804626A CA 2804626 A CA2804626 A CA 2804626A CA 2804626 C CA2804626 C CA 2804626C
Authority
CA
Canada
Prior art keywords
value
pattern
genes
rna
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2804626A
Other languages
English (en)
French (fr)
Other versions
CA2804626A1 (en
Inventor
Steven Shak
Frederick L. Baehner
Tara Maddala
Mark Lee
Robert J. Pelham
Wayne Cowens
Diana Cherbavaz
Michael C. Kiefer
Michael Crager
Audrey Goddard
Joffre B. Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MDxHealth SA
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Priority to CA3081061A priority Critical patent/CA3081061C/en
Publication of CA2804626A1 publication Critical patent/CA2804626A1/en
Application granted granted Critical
Publication of CA2804626C publication Critical patent/CA2804626C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2804626A 2010-07-27 2011-07-25 Method for using expression of glutathione s-transferase mu 2 (gstm2) to determine prognosis of prostate cancer Active CA2804626C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3081061A CA3081061C (en) 2010-07-27 2011-07-25 Method for using expression of klk2 to determine prognosis of prostate cancer

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US36821710P 2010-07-27 2010-07-27
US61/368,217 2010-07-27
US41431010P 2010-11-16 2010-11-16
US61/414,310 2010-11-16
US201161485536P 2011-05-12 2011-05-12
US61/485,536 2011-05-12
PCT/US2011/045253 WO2012015765A2 (en) 2010-07-27 2011-07-25 Method for using gene expression to determine prognosis of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3081061A Division CA3081061C (en) 2010-07-27 2011-07-25 Method for using expression of klk2 to determine prognosis of prostate cancer

Publications (2)

Publication Number Publication Date
CA2804626A1 CA2804626A1 (en) 2012-02-02
CA2804626C true CA2804626C (en) 2020-07-28

Family

ID=45527113

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2804626A Active CA2804626C (en) 2010-07-27 2011-07-25 Method for using expression of glutathione s-transferase mu 2 (gstm2) to determine prognosis of prostate cancer
CA3081061A Active CA3081061C (en) 2010-07-27 2011-07-25 Method for using expression of klk2 to determine prognosis of prostate cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3081061A Active CA3081061C (en) 2010-07-27 2011-07-25 Method for using expression of klk2 to determine prognosis of prostate cancer

Country Status (12)

Country Link
US (6) US20120028264A1 (enExample)
EP (5) EP4083233A3 (enExample)
JP (5) JP2013532482A (enExample)
AU (1) AU2011282892B2 (enExample)
CA (2) CA2804626C (enExample)
DK (3) DK2913405T3 (enExample)
ES (4) ES2537403T3 (enExample)
IL (5) IL243201A (enExample)
MX (4) MX338883B (enExample)
NZ (1) NZ607282A (enExample)
SG (3) SG186940A1 (enExample)
WO (1) WO2012015765A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155897A2 (en) * 2007-03-30 2010-02-24 Source Precision Medicine, Inc. d/b/a Source MDX. Gene expression profiling for identification, monitoring, and treatment of prostate cancer
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
WO2012030840A2 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
SG11201404390WA (en) 2012-01-31 2014-08-28 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer
TW201343920A (zh) * 2012-03-29 2013-11-01 Nat Health Research Institutes 預測前列腺癌預後之分子標記、方法與套組
BR102012007246A2 (pt) * 2012-03-30 2016-02-10 Fundação Antonio Prudente métodos para prognóstico e classificação de resultados de um evento
US20150104440A1 (en) * 2012-04-12 2015-04-16 Cornell University MiRNA-31 AS A DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC AGENT IN CANCER
GB201207722D0 (en) 2012-05-02 2012-06-13 Bergenbio As Method
US20150218646A1 (en) * 2012-07-20 2015-08-06 Diagnocure Inc Methods, kits and compositions for providing a clinical assessment of prostate cancer
CN102816862A (zh) * 2012-09-19 2012-12-12 南开大学 miRNA 222在前列腺癌血清学诊断试剂盒中的应用
WO2014071226A1 (en) * 2012-11-02 2014-05-08 The Regents Of The University Of California Methods and systems for determining a likelihood of adverse prostate cancer pathology
WO2014078700A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
US20160326594A1 (en) * 2013-12-30 2016-11-10 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer gene profiles and methods of using the same
CA2935720A1 (en) 2014-01-16 2015-07-23 Illumina, Inc. Gene expression panel for prognosis of prostate cancer recurrence
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2016037000A1 (en) * 2014-09-04 2016-03-10 Miodx Method of multivariate molecule analysis
WO2016115312A1 (en) 2015-01-14 2016-07-21 Ohio State Innovation Foundation Mirna-based predictive models for diagnosis and prognosis of prostate cancer
CA2976577C (en) 2015-02-11 2024-11-19 Univ Aarhus MICRORNA-BASED METHOD FOR THE EARLY DETECTION OF PROSTATE CANCER IN URINE SAMPLES
WO2016134727A1 (en) 2015-02-27 2016-09-01 Exiqon A/S A microrna-based method for assessing the prognosis of a prostate cancer patient
CN104880565A (zh) * 2015-05-04 2015-09-02 贵州省人民医院 Zfp36前列腺癌预后诊断的检测试剂及其试剂盒
BR112017025430B1 (pt) * 2015-05-29 2024-04-30 Koninklijke Philips N.V. Método, uso de um produto, produto de programa de computador e sistema
US20170107580A1 (en) 2015-10-15 2017-04-20 Dendreon Pharmaceuticals, Inc. Gene expression markers for predicting overall survival in subjects treated with sipuleucel-t
EP3405583B1 (en) * 2016-01-20 2024-04-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for screening and identifying clinically aggressive prostate cancer
WO2017136603A1 (en) * 2016-02-02 2017-08-10 Guardant Health, Inc. Cancer evolution detection and diagnostic
WO2017210662A1 (en) * 2016-06-03 2017-12-07 Castle Biosciences, Inc. Methods for predicting risk of recurrence and/or metastasis in soft tissue sarcoma
US10724089B2 (en) 2016-10-06 2020-07-28 The Board Of Trustees Of The University Of Illinois Spatial molecular analysis of tissue
WO2018098241A1 (en) * 2016-11-22 2018-05-31 University Of Rochester Methods of assessing risk of recurrent prostate cancer
GB201619808D0 (en) * 2016-11-23 2017-01-04 Univ London Queen Mary Biomarkers for the prognosis and diagnosis of cancer
CA3089406A1 (en) * 2018-01-25 2019-08-01 Sorbonne Universite Molecular signature and use thereof for the identification of indolent prostate cancer
PL3755816T3 (pl) * 2018-02-22 2025-06-30 Liquid Biopsy Research LLC Sposoby wykrywania i leczenia nowotworu gruczołu krokowego
WO2020214718A1 (en) * 2019-04-16 2020-10-22 Memorial Sloan Kettering Cancer Center Rrm2 signature genes as prognostic markers in prostate cancer patients
JP2020195314A (ja) * 2019-05-31 2020-12-10 医薬資源研究所株式会社 疾患・体質の分析方法、疾患・体質の分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体
CN114423874A (zh) * 2019-07-05 2022-04-29 英特莱克森有限责任公司 个体hla分型的确定方法及其作为预测因子、靶基因和治疗剂的用途
WO2021124455A1 (ja) * 2019-12-17 2021-06-24 株式会社 東芝 分析方法及びキット
CN114901821A (zh) * 2019-12-19 2022-08-12 豪夫迈·罗氏有限公司 Sept9抑制剂用于治疗乙型肝炎病毒感染的用途
US20230070840A1 (en) * 2020-01-30 2023-03-09 Arocell Ab Predicting patient survival
EP3885453A1 (en) * 2020-03-23 2021-09-29 Koninklijke Philips N.V. Prediction of radiotherapy response for prostate cancer subject based on dna repair genes
US11845993B2 (en) * 2020-03-24 2023-12-19 The Regents Of The University Of Michigan Methods for identifying prostate cancer
CA3186853A1 (en) * 2020-07-23 2022-01-27 John Mansell Compositions and methods for treating pain and anxiety disorders
ES1277194Y (es) 2021-03-25 2021-11-26 Keyzell Holding Sl Sistema basado en inteligencia artificial para analizar biomarcadores y personalizar tratamientos para cáncer
JPWO2024162265A1 (enExample) 2023-01-30 2024-08-08
CN116640734B (zh) * 2023-06-17 2025-01-24 青岛农业大学 关键基因在体外调控卵母细胞gvbd的用途及干扰片段

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6012696A (en) 1995-06-14 1997-01-15 Aberdeen University Prognostic and therapeutic system for cancer
US6300060B1 (en) 1995-11-09 2001-10-09 Dana-Farber Cancer Institute, Inc. Method for predicting the risk of prostate cancer morbidity and mortality
USRE38490E1 (en) 1995-11-16 2004-04-06 Baylor College Of Medicine Method for identifying metastatic sequences
US5712097A (en) 1996-01-19 1998-01-27 The Johns Hopkins University School Of Medicine Tumor suppressor gene, DPC4
WO1998002748A1 (en) 1996-07-15 1998-01-22 Mayo Foundation For Medical Education And Research Methods to detect hk2 polypeptides
US6479263B1 (en) 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
US6190857B1 (en) 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
WO1999004238A2 (en) 1997-07-15 1999-01-28 Mitotix, Inc. Reagents and methods for diagnosis and prognosis of proliferative disorders
US20030096742A1 (en) 1997-12-03 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
FI980488A7 (fi) 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
CA2330929A1 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
AU4158799A (en) 1998-06-06 1999-12-30 Genostic Pharma Limited Probes used for genetic filing
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2000040749A2 (en) 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
EP1151142A2 (en) * 1999-01-28 2001-11-07 Gen-Probe Incorporated Nucleic acid sequences for detecting genetic markers for cancer in a biological sample
US20030207808A1 (en) 1999-02-18 2003-11-06 Kinneret Savitzky Novel nucleic acid and amino acid sequences
FI990382A0 (fi) 1999-02-23 1999-02-23 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
WO2000061744A1 (fr) 1999-04-09 2000-10-19 Chugai Research Institute For Molecular Medicine, Inc. Nouveaux genes de foetus
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
GB9926805D0 (en) 1999-11-13 2000-01-12 Zeneca Ltd Diagnostic methods
ATE424457T1 (de) * 2000-01-13 2009-03-15 Genentech Inc Menschliche stra6 polypeptide
US6448086B1 (en) 2000-01-18 2002-09-10 Diagnostic Systems Laboratories, Inc. Insulin-like growth factor system and cancer
US6566130B1 (en) 2000-01-28 2003-05-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Androgen-regulated gene expressed in prostate tissue
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
AU2002214576A1 (en) 2000-10-13 2002-04-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genes related to development of refractory prostate cancer
WO2002037113A2 (en) 2000-11-03 2002-05-10 Michael Giesing Clinical and functional validation of targets from disseminated cancer cells
WO2002074156A2 (en) 2001-02-02 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20060088823A1 (en) 2001-03-29 2006-04-27 Brian Haab Microarray gene expression profiling in clear cell renal cell carcinoma : prognosis and drug target identification
WO2002097438A1 (en) 2001-05-25 2002-12-05 Mount Sinai Hospital Method of detecting and monitoring prostate and ovarian cancers
US20030138793A1 (en) 2001-06-10 2003-07-24 Irm Llc, A Delaware Limited Liability Company Molecular signatures of commonly fatal carcinomas
AU2002337657A1 (en) 2001-07-25 2003-02-17 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
US20100297657A1 (en) 2001-08-02 2010-11-25 The Regents Of The University Of Michigan Expression profile of prostate cancer
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US6964850B2 (en) 2001-11-09 2005-11-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20030148410A1 (en) 2001-12-10 2003-08-07 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
US6949342B2 (en) 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
US20030215835A1 (en) 2002-01-15 2003-11-20 Zairen Sun Differentially-regulated prostate cancer genes
US20050112705A1 (en) 2002-03-14 2005-05-26 Laurent Bracco Variants of human kallikrein-2 and kallikrein-3 and uses thereof
AUPS187002A0 (en) * 2002-04-22 2002-05-30 Queensland University Of Technology Condition-specific molecules and uses therefor
EP1552293A4 (en) 2002-09-10 2006-12-06 Guennadi V Glinskii METHOD FOR SEGREGATION OF GENES AND CLASSIFICATION OF BIOLOGICAL SAMPLES
EP1585433A4 (en) 2002-09-25 2008-01-23 Ge Healthcare Sv Corp DETECTION METHODS
WO2004053106A2 (en) 2002-12-05 2004-06-24 Regulome Corporation Profiled regulatory sites useful for gene control
JP4824540B2 (ja) 2003-02-07 2011-11-30 ダイアノキュアー インク． サンプル中の前立腺癌を検出する方法
WO2004077942A2 (en) 2003-02-28 2004-09-16 Genpath Pharmaceuticals, Incorporated Inducible prostate cancer model
EP1620573A4 (en) 2003-04-15 2006-12-20 Avalon Pharmaceuticals DETERMINATION OF CANCER-ASSOCIATED GENES AND THERAPEUTIC OBJECTS USING MOLECULAR CYTOGENETIC PROCEDURES
US7659062B2 (en) * 2003-06-03 2010-02-09 The Board of Trustee of the University of Arkansas System Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
WO2005039382A2 (en) 2003-06-24 2005-05-06 Genomic Health Prediction of likelihood of cancer recurrence
EP1644858B1 (en) * 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
CA2533803A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
AU2004298604B2 (en) 2003-12-15 2010-09-23 The Regents Of The University Of California Molecular signature of the PTEN tumor suppressor
JP2008504803A (ja) 2004-01-09 2008-02-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 遺伝子発現の細胞型特異的パターン
GB0400976D0 (en) 2004-01-16 2004-02-18 Univ Cambridge Tech Methods of diagnosis
WO2005076005A2 (en) 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
JP2005211023A (ja) 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
WO2005083128A2 (en) 2004-02-25 2005-09-09 University Of South Florida Methods for predicting cancer outcome and gene signatures for use therein
CA2848463A1 (en) 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US20070224596A1 (en) 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
JP4511592B2 (ja) 2004-04-29 2010-07-28 ラマエル，マルク サンプル中の成分を検出するための方法およびキット
AU2005245815B2 (en) 2004-05-07 2011-06-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
JP2008500057A (ja) 2004-05-27 2008-01-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｉｍｐｄｈ経路の阻害をモニタリングするためのバイオマーカー
EP1756309A2 (en) 2004-06-03 2007-02-28 Bayer HealthCare AG Methods for predicting and monitoring response to cancer therapy
WO2006005043A2 (en) 2004-06-30 2006-01-12 Cemines, Inc. Compositions and methods for detecting protein interactions with target dna sequences
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
CN101018874A (zh) 2004-08-13 2007-08-15 千年药品公司 用于鉴定、评估、预防和治疗前列腺癌的基因、组合物、试剂盒和方法
US7572640B2 (en) 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
CA3061785A1 (en) * 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
EP1824995A2 (en) 2004-11-24 2007-08-29 St. George's Enterprises Limited Diagnosis of prostate cancer
MX2007007401A (es) 2004-12-17 2007-10-08 Johnson & Johnson Metodos para evaluar a pacientes con leucemia mieloide aguda.
US7943306B2 (en) 2005-01-12 2011-05-17 The Board Of Trustees Of The Leland Stanford Junior University Gene expression signature for prediction of human cancer progression
JP2008536480A (ja) 2005-02-17 2008-09-11 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 癌の同定、評価、予防、および治療用組成物、キット、および方法、ならびに癌の治療法
US7666595B2 (en) * 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
WO2006110264A2 (en) * 2005-03-16 2006-10-19 Sidney Kimmel Cancer Center Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
WO2006105642A1 (en) 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
EP1869222A4 (en) 2005-04-15 2010-01-20 Oncomethylome Sciences S A METHYLATION MARKERS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
US20080275652A1 (en) 2005-05-13 2008-11-06 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
EP1910564A1 (en) 2005-05-13 2008-04-16 Duke University Gene expression signatures for oncogenic pathway deregulation
US20060292610A1 (en) 2005-06-06 2006-12-28 Regents Of The University Of Michigan Prognostic meta signatures and uses thereof
JP5904569B2 (ja) 2005-06-08 2016-04-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療を受けている患者の同定、判定および処置のための方法
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7718369B2 (en) * 2005-09-12 2010-05-18 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP1951911A2 (en) 2005-11-08 2008-08-06 Euclid Diagnostics LLC Materials and methods for assaying for methylation of cpg islands associated with genes in the evaluation of cancer
JP5984324B2 (ja) 2005-12-01 2016-09-06 メディカル プログノシス インスティテュート エー／エス 治療反応のバイオマーカーを同定するための方法および装置、ならびに治療効果を推定するためのその使用
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP1960547A2 (en) 2005-12-08 2008-08-27 Novartis AG Effects of inhibitors of fgfr3 on gene transcription
US20090215054A1 (en) 2005-12-13 2009-08-27 Carter Scott L Prognosis indicators for solid human tumors
WO2007075672A2 (en) 2005-12-23 2007-07-05 Lankenau Institute For Medical Research Prognostic cancer markers
KR20090003178A (ko) 2006-01-11 2009-01-09 게노믹 헬쓰, 인코포레이티드 직장결장암 예후에 대한 유전자 발현 마커
ES2300176B1 (es) * 2006-02-15 2009-05-01 Consejo Superior Investig. Cientificas Metodo para el diagnostico molecular de cancer de prostata, kit para implementar el metodo.
US20070218512A1 (en) 2006-02-28 2007-09-20 Alex Strongin Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
US20090098538A1 (en) 2006-03-31 2009-04-16 Glinsky Gennadi V Prognostic and diagnostic method for disease therapy
US7914988B1 (en) 2006-03-31 2011-03-29 Illumina, Inc. Gene expression profiles to predict relapse of prostate cancer
WO2007140352A2 (en) 2006-05-26 2007-12-06 Invitrogen Corporation Plasma membrane and secreted cancer biomarkers
WO2007149965A2 (en) 2006-06-22 2007-12-27 Wisconsin Alumni Research Foundation Stromal collagen in the diagnosis and characterization of breast cancer
WO2008036717A2 (en) 2006-09-19 2008-03-27 Emory University Use of soluble galectin-3 (gal-3) for cancer treatment
WO2008048570A2 (en) 2006-10-16 2008-04-24 The Ohio State University Research Foundation Piwil2-related biomarkers and cell lines useful therewith
WO2008046510A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Fn1 as a biomarker, therapeutic and diagnostic target
WO2008067065A2 (en) * 2006-10-19 2008-06-05 Shiv Srivastava Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
WO2008061104A2 (en) 2006-11-13 2008-05-22 Invitrogen Corporation Methods and kits for detecting prostate cancer biomarkers
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
WO2008070160A2 (en) 2006-12-06 2008-06-12 Avalon Pharmaceuticals, Inc. Cancer-linked genes as biomarkers to monitor response to impdh inhibitors
AT504702A1 (de) 2006-12-22 2008-07-15 Arc Austrian Res Centers Gmbh Set von tumormarkern
EP2102356A2 (en) 2007-01-09 2009-09-23 Brystol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in prostate cells
US20090047694A1 (en) 2007-08-17 2009-02-19 Shuber Anthony P Clinical Intervention Directed Diagnostic Methods
CA2680591A1 (en) 2007-03-15 2008-09-25 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2008122447A2 (en) 2007-04-10 2008-10-16 Epigenomics Ag Dna methylation assay for the diagnosis or prognosis of medical conditions
EP2639315A1 (en) 2007-05-11 2013-09-18 The Johns Hopkins University Biomarkers for melanoma
US20110030074A1 (en) 2007-05-21 2011-02-03 Dana Farber Cancer Institute, Inc. Compositions and methods for cancer gene discovery
US20110136123A1 (en) 2007-08-15 2011-06-09 Universite De Sherbrooke Alternative splicing gene variants in cancer
JP2010537658A (ja) 2007-09-07 2010-12-09 ユニヴェルシテ リブル ドゥ ブリュッセル Ｈｅｒ２＋患者におけるガンの予後判定のための方法およびツール
WO2009051734A1 (en) 2007-10-17 2009-04-23 The General Hospital Corporation Microchip-based devices for capturing circulating tumor cells and methods of their use
GB0721605D0 (en) 2007-11-02 2007-12-12 Cancer Rec Tech Ltd Prostrate cancer susceptibility screening
US20090123439A1 (en) 2007-11-09 2009-05-14 The Jackson Laboratory Diagnostic and prognosis methods for cancer stem cells
WO2009070767A2 (en) 2007-11-28 2009-06-04 Whitehead Institute For Biomedical Research Systemic instigation systems to study tumor growth or metastasis
EP2065474A1 (en) 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH A method to assess prognosis and to predict therapeutic response to endocrine treatment
WO2009068423A2 (en) 2007-11-30 2009-06-04 Siemens Healthcare Diagnostics Gmbh Method for predicting therapy responsiveness in basal like tumors
WO2009089521A2 (en) 2008-01-10 2009-07-16 Nuvera Biosciences, Inc. Predictors for evaluating response to cancer therapy
WO2009105154A2 (en) 2008-02-19 2009-08-27 The Jackson Laboratory Diagnostic and prognostic methods for cancer
WO2009105640A1 (en) 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
SG177938A1 (en) 2008-03-26 2012-02-28 Theranos Inc Methods and systems for assessing clinical outcomes
EP2105511A1 (en) 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
WO2009124251A1 (en) 2008-04-03 2009-10-08 Sloan-Kettering Institute For Cancer Research Gene signatures for the prognosis of cancer
EP2288722B1 (en) 2008-04-10 2014-11-05 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations
WO2009132257A2 (en) 2008-04-25 2009-10-29 Integrated Bioscience Solutions, Llc Cytological methods for detecting cancer
US8093000B2 (en) 2008-05-09 2012-01-10 The Regents Of The University Of California Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation
CN102027373B (zh) 2008-05-14 2017-10-10 埃斯苏黎世公司 发现用于前列腺癌诊断和治疗之生物标志物和药物靶标的方法及其确立的生物标志物测定
CN102099491A (zh) 2008-05-15 2011-06-15 北卡罗来纳-查佩尔山大学 调节血管生成的新靶标
WO2009140741A1 (en) 2008-05-23 2009-11-26 The University Of Queensland Agents and methods for diagnosing the presence or risk of prostate cancer
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
GB0809689D0 (en) 2008-05-28 2008-07-02 Cancer Res Inst Royal Markers for prostate cancee
US20090298082A1 (en) * 2008-05-30 2009-12-03 Klee George G Biomarker panels for predicting prostate cancer outcomes
WO2009149166A2 (en) 2008-06-03 2009-12-10 Children's Hospital Medical Center Methods and compositions for the diagnosis and treatment of proliferative disorders
RU2011101378A (ru) 2008-06-16 2012-07-27 Сайвидон Дайагностикс Гмбх (De) Алгоритмы предсказания исхода у пациентов с узловой формой рака молочной железы после химиотерапии
US20120009581A1 (en) 2008-07-08 2012-01-12 Bankaitis-Davis Danute M Gene Expression Profiling for Predicting the Survivability of Prostate Cancer Subjects
MX2011000451A (es) 2008-07-16 2011-10-12 Dana Farber Cancer Inst Inc Distintivos y determinantes asociados con cancer de próstata y métodos para utilizarlos.
NZ590993A (en) 2008-07-21 2012-11-30 Translational Genomics Res Inst Dual specificity phosphatase 1 protein (DUSP1) for diagnosis and prognosis of skin cancer
DK2324111T3 (da) 2008-09-10 2013-09-30 Life & Brain Gmbh Yderzone-tumorceller samt fremgangsmåde til fremstilling deraf samt anvendelse deraf
JP5819728B2 (ja) 2008-10-20 2015-11-24 ファーマテスト・サービシーズ・オサケユキテュアＰｈａｒｍａｔｅｓｔ Ｓｅｒｖｉｃｅｓ Ｏｙ Ｎａｖ３の遺伝子異常および複数遺伝子の異常発現を含む方法および使用
AU2009307651A1 (en) 2008-10-22 2010-04-29 Genentech, Inc. Prostate stem cells and uses thereof
US7888035B2 (en) 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
US20110230361A1 (en) * 2008-11-14 2011-09-22 Emory University Prostate cancer biomarkers to predict recurrence and metastatic potential
US20110230372A1 (en) 2008-11-14 2011-09-22 Stc Unm Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and outcome prediction in pediatric b-precursor acute lymphoblastic leukemia
GB0821787D0 (en) 2008-12-01 2009-01-07 Univ Ulster A genomic-based method of stratifying breast cancer patients
WO2010065940A1 (en) 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
CA2748823A1 (en) 2009-01-06 2010-07-15 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for the identification, monitoring, and treatment of prostate cancer
EP3524697B1 (en) 2009-01-07 2024-10-02 Myriad Genetics, Inc. Cancer biomarkers
NZ628463A (en) 2009-01-14 2015-12-24 Us Health Ratio based biomarkers and methods for use thereof
EP2387717B1 (en) 2009-01-15 2014-12-10 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-2 expression
EP2233590A1 (en) 2009-01-28 2010-09-29 AIT Austrian Institute of Technology GmbH Methylation assay
AU2010215838A1 (en) 2009-02-20 2010-08-26 John Wayne Cancer Institute B7-H3 antibody coupled bead assay for detection of circulating tumor cells
WO2010099577A1 (en) 2009-03-04 2010-09-10 The University Of Queensland Cancer biomarkers and uses therefor
US8639733B2 (en) 2009-03-16 2014-01-28 Apple Inc. Automatic identification of compatible applications and accessories
US8765383B2 (en) 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
EP2241634A1 (en) 2009-04-16 2010-10-20 Université Libre de Bruxelles Diagnostic method and tools to predict the effiacy of targeted agents against IGF-1 pathway activation in cancer
AU2010237568A1 (en) 2009-04-16 2011-11-17 National Research Council Of Canada Process for tumour characteristic and marker set identification, tumour classification and marker sets for cancer
WO2010127399A1 (en) 2009-05-06 2010-11-11 Walter And Eliza Hall Institute Of Medical Research Gene expression profiles and uses thereof
WO2010129965A1 (en) 2009-05-08 2010-11-11 The Regents Of The University Of California Cancer specific mitotic network
US20100303795A1 (en) * 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
EA021945B1 (ru) 2009-07-08 2015-10-30 Уорлдуайд Иновейтив Нетуорк Способ прогнозирования эффективности лекарственных соединений для пациента
WO2011039734A2 (en) 2009-10-02 2011-04-07 Enzo Medico Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer
WO2011063274A2 (en) 2009-11-23 2011-05-26 Genomic Health, Inc. Methods to predict clinical outcome of cancer
CA3256492A1 (en) 2010-01-11 2025-11-29 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
WO2014108896A1 (en) 2013-01-08 2014-07-17 Marpe Technologies Ltd. Device and method for body moles mapping and tracking

Also Published As

Publication number Publication date
US20200255911A1 (en) 2020-08-13
CA3081061C (en) 2023-01-03
SG10201505769PA (en) 2015-09-29
EP2598659B1 (en) 2015-03-11
US10260104B2 (en) 2019-04-16
IL251403A0 (en) 2017-05-29
ES2537403T3 (es) 2015-06-08
EP4083233A2 (en) 2022-11-02
EP4083233A3 (en) 2023-01-25
IL243205A (en) 2017-04-30
MX346031B (es) 2017-03-01
ES2925983T3 (es) 2022-10-20
EP3556870B1 (en) 2022-06-22
DK2598659T3 (en) 2015-05-26
EP3147373A1 (en) 2017-03-29
IL243203A (en) 2017-04-30
IL251403B (en) 2018-04-30
CA2804626A1 (en) 2012-02-02
EP3556870B9 (en) 2022-09-28
JP2013532482A (ja) 2013-08-19
IL243206A (en) 2017-04-30
JP6246845B2 (ja) 2017-12-13
JP7042784B2 (ja) 2022-03-28
EP3556870A1 (en) 2019-10-23
IL243201A (en) 2017-04-30
JP2016178921A (ja) 2016-10-13
AU2011282892B2 (en) 2015-07-16
US20160097105A1 (en) 2016-04-07
AU2011282892A1 (en) 2013-03-07
MX2018011725A (es) 2021-11-16
DK3147373T3 (da) 2019-08-12
MX359416B (es) 2018-09-27
MX338883B (es) 2016-05-04
WO2012015765A2 (en) 2012-02-02
EP2913405B1 (en) 2016-11-09
HK1212395A1 (en) 2016-06-10
DK2913405T3 (en) 2017-02-13
ES2741745T3 (es) 2020-02-12
SG186940A1 (en) 2013-02-28
NZ607282A (en) 2014-06-27
US20250129432A1 (en) 2025-04-24
EP2598659A4 (en) 2014-01-01
ES2611000T3 (es) 2017-05-04
US20120028264A1 (en) 2012-02-02
CA3081061A1 (en) 2012-02-02
EP2598659A2 (en) 2013-06-05
HK1185116A1 (en) 2014-02-07
JP2022031750A (ja) 2022-02-22
JP2020031642A (ja) 2020-03-05
MX2013000996A (es) 2013-12-09
EP2913405A1 (en) 2015-09-02
US20190249260A1 (en) 2019-08-15
US20220396842A1 (en) 2022-12-15
WO2012015765A3 (en) 2012-06-14
EP3147373B1 (en) 2019-05-15
SG10201912361VA (en) 2020-02-27
JP2018068299A (ja) 2018-05-10

Similar Documents

Publication Publication Date Title
US20250129432A1 (en) Method for Using Gene Expression to Determine Prognosis of Prostate Cancer
EP2504451B1 (en) Methods to predict clinical outcome of cancer
AU2017268510B2 (en) Method for using gene expression to determine prognosis of prostate cancer
HK40014991B (en) Method for using gene expression to determine prognosis of prostate cancer
HK40014991A (en) Method for using gene expression to determine prognosis of prostate cancer
HK1235085B (en) Method for using gene expression to determine prognosis of prostate cancer
HK1235085A1 (en) Method for using gene expression to determine prognosis of prostate cancer
HK40107615A (en) Methods to predict clinical outcome of cancer
HK1212395B (en) Method for using gene expression to determine prognosis of prostate cancer
HK40043378A (en) Methods to predict clinical outcome of cancer
HK1175820B (en) Methods to predict clinical outcome of cancer
HK1175820A (en) Methods to predict clinical outcome of cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160517